EpCAM/TROP1 Antibody (VU-1D9)

Epithelial cell adhesion molecule (EpCAM), also known as TROP1 and CD326, is a type I transmembrane glycoprotein that plays a role in a number of cellular processes including adhesion, signaling, maintaining stemness, proliferation, migration, and invasion (1,2). The human EpCAM protein is 314 amino acids (aa) in length with a theoretical molecular weight (MW) of ~35 kDa (1,3,4). The EpCAM protein includes a signal peptide, an extracellular N-terminal domain, a thyroglobulin type-1 domain, a carboxyl-terminal domain, a single-pass transmembrane domain, and an intracellular domain (1,3). The protein is highly conserved and has approximately 81% aa sequence identity between human and mouse (5). Trophoblast cell-surface antigen 2 (TROP2) also shares ~67% aa sequence similarity with EpCAM (1,5). While both EpCAM and TROP2 are cell surface markers expressed in the epithelium, their expression levels typically do not correlate (5). EpCAM is expressed in normal epithelial tissue and elevated expression is observed in many epithelial carcinomas (1-3) Patient tumor samples with increased EpCAM expression have been associated with poor prognosis (1). Given EpCAM's elevated expression in tumors, it has become a potential target for cancer therapy approaches, including monoclonal antibody treatment and anti-EpCAM trispecific antibodies (1,5).

EpCAM functions as an intracellular signaling molecule and contributes to regulation of epithelial-to-mesenchymal (EMT) transition (4,5). EpCAM is cleaved during the process of regulated intramembrane proteolysis (RIP) (4,5). Initial cleavage occurs at the membrane via a disintegrin and metalloprotease 17 (ADAM17) which releases EpCAM's extracellular domain (EpEx) (4,5). A secondary cleavage is mediated by presenilin 2 (PSEN2) which releases EpCAM's cytoplasmic trail (EpICD) (4,5). EpICD translocates to the nucleus where it associates with beta-catenin, FHL-2, and LEF-1 and induces transcription of genes related to EMT and tumor growth (4,5). EpCAM has also been shown to regulate structure and functionality of the apical junction complex of cells through direct interaction with claudin-7 and association with E-cadherin (2,5). Loss of EpCAM disrupts adherins junction and tight junction structure and function (2).

References

1. Mohtar MA, Syafruddin SE, Nasir SN, Low TY. Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. Biomolecules. 2020; 10(2):255. https://doi.org/10.3390/biom10020255

2. Huang L, Yang Y, Yang F, et al. Functions of EpCAM in physiological processes and diseases (Review). Int J Mol Med. 2018; 42(4):1771-1785. https://doi.org/10.3892/ijmm.2018.3764

3. Brown TC, Sankpal NV, Gillanders WE. Functional Implications of the Dynamic Regulation of EpCAM during Epithelial-to-Mesenchymal Transition. Biomolecules. 2021; 11(7):956. https://doi.org/10.3390/biom11070956

4. Uniprot (P16422)

5. Schnell U, Cirulli V, Giepmans BN. EpCAM: structure and function in health and disease. Biochim Biophys Acta. 2013; 1828(8):1989-2001. https://doi.org/10.1016/j.bbamem.2013.04.018

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Rat.

We have publications tested in 3 applications: Flow, ICC/IF, WB.

Showing Publications 1 - 9 of 9.

Publications using NBP2-33051	Applications	Species
Mavroudis D, Sotiriou A I et al Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy Cancers (Basel) 2020-06-18 [PMID: 32545559] (ICC/IF, Human) Details: Citation using the Azide and BSA Free version of this antibody.	ICC/IF	Human
Pailler E, Faugeroux V, Oulhen M et al Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer. Clin Cancer Res. 2019-08-22 [PMID: 31439588] (ICC/IF, Human) Details: Citation using the Alexa Fluor 488 version of this antibody.	ICC/IF	Human
Wang SJ, Asthana S, van Zante A et al. Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient Oral Oncol. 2017-04-02 [PMID: 28559012] (WB, Human)	WB	Human
Massard, C, Oulhen, M Et al. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study. Oncotarget Aug 23 2016 [PMID: 27391263] (Flow, Rat)	Flow	Rat
Brunner A, Prelog M, Verdorfer I et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder J Clin Pathol 2008-03-01 [PMID: 17586680] Details: This reference used the PE version of NBP2-33051.
Winter MJ, Nagtegaal ID, van Krieken JH et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology Am J Pathol 2003-12-01 [PMID: 14633587] Details: This reference used the PE version of NBP2-33051.
Li G, Passebosc-Faure K, Lambert C et al. Flow cytometric analysis of antigen expression in malignant and normal renal cells Anticancer Res 2000-07-01 [PMID: 10953356] Details: This reference used the PE version of NBP2-33051.
Ogura E, Senzaki H, Yoshizawa K et al. Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors Anticancer Res 1998-09-01 [PMID: 9854475] Details: This reference used the PE version of NBP2-33051.
Tsubura A, Senzaki H, Sasaki M et al. Immunohistochemical demonstration of breast-derived and/or carcinoma-associated glycoproteins in normal skin appendages and their tumors J Cutan Pathol 1992-02-01 [PMID: 1556271] Details: This reference used the PE version of NBP2-33051.

Array NBP2-33051

• EpCAM/TROP1 Antibodies
• EpCAM/TROP1 Antibody Pairs
• EpCAM/TROP1 ELISA Kit
• EpCAM/TROP1 Proteins
• EpCAM/TROP1 ELISA
• EpCAM/TROP1 Proteins and Enzymes